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ABSTRACT Fibroblast growth factor 2 (FGF2) can enhance the proliferative capacity of bone and bone marrow stromal cells;
however, the mechanisms behind this effect are not well described. We present a whole-cell kinetic model relating receptor-
mediated binding, internalization, and processing of FGF2 to osteoblastic proliferative response. Focusing on one of the po-
tential signaling complex stoichiometries, we utilized experimentally measured and modeled estimated rate constants to predict
in vitro proliferation and distinguish between potential binding orders. We found that piecewise assemblage of a ternary
signaling complex may occur in several ways depending on the local binding environment. Using experimental data of
endocytosed FGF2 as a constraint, we have also shown evidence of potential multistep processes involved in heparan-sulfate
proteoglycans-bound FGF2 release, internalization, and fragment formation in conjunction with the normal metabolism of the
proteoglycan.
INTRODUCTION
The ease with which bone marrow stromal cells (BMSCs)
can be isolated from a patient and expanded in vitro, com-
bined with their robust osteoblastic lineage potential (1),
make them an attractive cell source for bone tissue engi-
neering research. However, upon in vitro expansion, the
proliferation rate (2) and bone-forming efﬁciency of BMSCs
(3) decreases with increasing passage number. These limi-
tations have caused concern regarding the use of BMSCs in
clinical applications. There have been a number of studies
investigating various biological additives to help overcome
these shortcomings (4–6). Of particular multifaceted beneﬁt,
ﬁbroblast growth factor 2 (FGF2) enhances the osteogenic
potential of BMSCs (7) and extends their lifespan (8) as well
as proliferative capacity (7,8). As part of our program in
bone tissue engineering, we have developed a whole-cell
kinetic model to investigate the mechanisms through which
FGF2 induces bone and BMSC proliferation. By continuing
to gain insight on dynamic receptor-ligand interactions and
subsequent cellular response, researchers will eventually
develop a systematic framework through which to maximize,
exploit, and control the use of FGF2 in bone tissue engi-
neering applications.
Fibroblast growth factor 2 (FGF2) is a pluripotent and
pleiotropic member of a family of polypeptides that regulate
cell-growth and differentiation, play a major role in tissue
development, tissue repair, and tissue regeneration, and are
implicated in a number of pathologies (9). FGF2 is mitogenic
for several cells of mesodermal, ectodermal, and endodermal
origin (10). Several mathematical models have surfaced on
FGF2 binding, providing information on: the impact of
heparan-sulfate proteoglycans (HSPGs) on FGF2-FGFR
binding (11); translocation through the basement membrane
(12); how HSPG regulates and impacts FGFR binding (13);
FGF2 signaling pathways (14); receptor interactions in sig-
naling (15); receptor preassociation (16); signal complex
assembly (17); and the correlation between surface-binding
kinetics and the activation of downstream mediators of re-
sponse (18). The model presented here focuses on, but is not
limited to, the impact of FGF2 on primary and BMSC-derived
osteoblast proliferation. This article will explore the use of
kinetic constants derived from osteoblastic and other meso-
dermal cells in a whole-cell kinetic model to determine if they
can be used to predict average in vitro bone cell mitogenic
response and to explore the intracellular fate of FGF2.
Exogenous 18-kDa FGF2 stimulation of proliferation
occurs through dimerization of high afﬁnity ﬁbroblast
growth factor receptors (FGFRs) (19). This low molecular
mass form of FGF2 is known to act in an autocrine/paracrine
manner (20). Higher molecular-weight isoforms of FGF2
(22, 22.5, 24, and 34 kDa) are localized in the nucleus, are
not released from the cell, and act through intracrine mech-
anisms (21–24). Five FGFRs have been identiﬁed (25,26),
with FGFR1–4 containing intracellular tyrosine kinase
domains. FGF2 also interacts with a class of low-afﬁnity
receptors, the heparin-like glycosaminoglycan component of
heparan-sulfate proteoglycans (HSPGs). HSPGs/heparin are
involved in the signaling complex that promotes mitogenesis
(27–29) without directly altering the signal transduction
pathways activated by occupied FGFRs (30). Ligand-
induced receptor dimerization and subsequent autophos-
phorylation of the intracellular tyrosine kinase domains
initiates multiple signal-transduction pathways. Several of
these pathways may be interdependent (31) and a number of
parallel pathways likely contribute to mitogenic signal
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transduction (32). Dimerization of FGFRs by FGF2 is
known to activate several mitogen-activated protein kinase
pathways including the extracellular signal-related kinases
1 and 2 (ERK 1/2) (31), which are involved in the regulation
of mitosis (28,33,34). The exact schema of intracellular sig-
naling events leading to FGF2-induced proliferation remains
illusive. In this article, we will focus on the salient ligand and
receptor trafﬁcking events that initiate the signaling path-
ways leading to mitogenesis, rather than the signaling cas-
cades themselves.
All receptor tyrosine kinases are activated by dimerization
(35), however, the speciﬁc mechanisms through which FGF
receptor dimerization is achieved are not clear (32), nor is
receptor activation alone enough to stimulate 18 kDa FGF2-
induced proliferation (36). After activation and ligand-
induced receptor endocytosis, exogenous FGF2 has been
shown to accumulate in the nucleus (37). Nuclear translo-
cation of FGF2 has been implicated as a requirement for
exogenous growth factor-induced mitogenic activity (38,39).
This is suggestive of an intracrine growth-promoting effect
of exogenous FGF2, which is synergistic with its autocrine-
signaling mechanisms (40). FGFRs have been found to translo-
cate to the nuclear membrane in response to FGF2 stimulation
(41–43), where they are involved in the regulation of cell
proliferation (44). HSPGs have also been implicated in FGF2
nuclear transport (45,46).
Three potential stoichiometries accounting for a signaling
complex involving FGFR dimerization have been suggested.
Crystal structure models for the two prototypic members of
the FGF family have been solved involving an FGF/heparin/
FGFR signaling complex with a 2:2:2 (using FGF2) (47) and
2:1:2 (48,49) (using FGF1) stoichiometry. In addition, an
alternate model based on biophysical analysis suggests a
ternary complex in which FGF2-bound HSPG promotes
FGFR dimerization (1:1:2) (50). In this article, we will focus
on the 2:2:2 stoichiometry and reserve the other conﬁgura-
tions for future examination. The authors of the 2:2:2 crystal
structure model (47) suggest that heparin interacts with both
FGF and FGFR to form a stable 1:1:1 ternary complex which
is subsequently recruited by an additional 1:1:1 complex to
form the signaling unit. Here, we constructed a model to
evaluate three potential binding orders for the formation of a
1:1:1 complex en route to receptor dimerization. We used
kinetic rate constants found in the literature (when available)
to compare mitogenic signaling complex formation in each
binding order to an average proliferative dose response ob-
served in osteoblastic cells. We have included an intracel-
lular component to this model to reconstruct potential
intracellular trafﬁcking events based on the limited knowl-
edge available regarding the destiny of endocytosed FGF2.
In addition, model predictions of cell-surface and media-
excreted HSPG concentrations are compared to experimental
values found in the literature.
The whole-cell kinetic model presented in this article is
able to predict average proliferative dose-response values for
osteoblastic cells in vitro. Using experimental proliferation
data collected in this lab and in the literature as a constraint,
we used the model to estimate kinetic rate constants not
available within the literature and evaluated their physiolog-
ical relevance. We assessed estimated kinetic rate constants
as well as cell model variables such as cell density, receptor
ratio, and the capacity of HSPG-ligand binding for their
ability to inﬂuence proliferation predictions. We found,
given the literature and estimated kinetic rate values, that
each binding conﬁguration could be of physiological rele-
vance and that the mode of signaling complex formation may
depend on the given local binding environment—including
the number, type, and distribution of receptors. We also ex-
plored implications that the presence and structure of HSPGs
may play an important role in the regulation of FGF2-
mediated proliferative response and bioavailability of the
growth factor. Intracellularly, it appears that there may be
multistep processes involving the endocytosis and process-
ing of FGF2 at high concentrations. Taken together, this
cellular model provides a succinct means of exploring the
relevance of both established and estimated kinetic rate con-
stants on the formation and subsequent internalization of an
FGF2-induced proliferative signaling complex. It is the ﬁrst
model of its kind to incorporate the intracellular processing
of FGF2 and utilize an experimentally observed common-
ality in proliferative dose response across two types of bone
cells in two species as an analytical constraint for surface-
binding events. As modeling in this ﬁeld grows, this type of
analysis of the complex FGF-FGFR system may eventually
provide a means of understanding, controlling, and manip-
ulating this signaling process for the beneﬁt of biological,
engineering, and clinical sciences.
MATERIALS AND METHODS
Experimental methods
Cell isolation and culture
Marrow and bone cells were isolated from the tibias and femurs of young
male New Zealand White rabbits (average 1.67 kg). Bone marrow cavity
contents were aseptically removed and harvested in Dulbecco’s Modiﬁed
Eagle’s Medium containing 50 mg/mL gentamicin. Marrow was passed
through 18- and 20-gauge needles and resuspended in medium containing
Dulbecco’s Modiﬁed Eagle’s Medium supplemented with 10% fetal bovine
serum (FBS), 2.5 mM L-glutamine, and 50 mg/mL gentamicin. To induce
osteogenic differentiation, media also was supplemented with 108 M dexa-
methasone, 50 mg/ml ascorbic acid, and 3 mM b-glycerophosphate (BMSC
growth media). Nucleated hematopoietic and stromal cells were plated in
tissue culture polystyrene ﬂasks at 6.7 3 105 cells/cm2. Cells were cultured
in a humidiﬁed 37C/5% CO2 incubator. BMSCwere selected based on their
ability to adhere to the ﬂask; nonadherent hematopoietic cells were removed
upon reseeding after 24 h. Medium was replaced twice weekly until the cells
reached conﬂuence (;2.5 weeks), detached using a 0.25% trypsin/1 mM
ethylenediamine tetraacetic acid (EDTA) solution, and counted using a
Coulter Counter (Coulter Electronics, Hialeah, FL).
Periosteum and adherent tissue were removed from rabbit tibial and
femoral bone chips with a scalpel and rinsed in phosphate buffered saline
without calcium and magnesium. Chips were subjected to three sequential
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collagenase digestions (50 mg collagenase, 50 ml phosphate buffered saline,
and 2.5 ml FBS ﬁltered through 0.8 mm then 0.2 mm ﬁlters) for 30 min each
in a water bath (37C). Cell pellets were collected after centrifugation at
2000 RPM for 3 min. The ﬁrst pellet, primarily ﬁbroblastic cells (51), was
discarded. The remaining two digestions were plated in tissue culture poly-
styrene ﬂasks with HAM’s F-12 media supplemented with 10% FBS, 2.5
mM L-glutamine, and 3 mM b-glycerophosphate (bone cell growth media)
at 1 3 104 cells/cm2. Medium was replaced twice weekly until the cells
reached conﬂuence (;2 weeks), detached using a 0.25% trypsin/0.02%
EDTA solution, and counted using a Coulter Counter.
FGF2 proliferation dose response
Rabbit bone cells and BMSCs were plated in 24 well plates at 13 104 cells/
cm2 in cell growth media and allowed to adhere for 24 h. Media then was
replaced with fresh cell growth media supplemented with various doses of
FGF2 (0, 0.01, 0.1, 1, 10, and 100 ng/ml). After ﬁve days of exposure, FGF2
supplemented media was replaced with fresh cell growth media without
FGF2. On day seven, cells were detached using a 0.25% trypsin/0.02%
EDTA solution, and counted using a Coulter Counter (n ¼ 4). Results are
presented in Table 1.
Proliferation data was also gathered from previously published exper-
iments performed by other independent laboratories (52,53). In those
studies, rat bone marrow stromal cell proliferation was measured by deter-
mining cell number using a methylene blue absorbance assay (53). Cells
were exposed to growth factor for ﬁve days at speciﬁed doses cultured for a
total of 14 days before data was collected. Rat calvarie data was collected by
measuring DNA synthesis through [3H]thymidine incorporation (52). Cells
were cultured in the continuous presence of FGF2 at speciﬁc doses for 96 h.
Cells were exposed to 5 mCi/ml of [3H]thymidine for the last 2 h before data
collection.
Rat and rabbit bone and bone marrow stromal cell dose response results
are presented in Fig. 1 along with their average. To normalize the four sets of
data and explore the similar pattern of FGF2 induced proliferative dose
response, all data is presented as a percentage of maximum response in cell
growth. This experimental average is used to compare model predictions
with cell response. The model proposed uses receptor ternary signaling com-
plex occupancy as a means to predict the proliferative response of cells
exposed to FGF2. The baseline for the experimentally measured prolifer-
ation for cells not exposed to FGF2 (0 ng/ml) was subtracted from experi-
mentally measured values at all doses.
The standard deviation between the values given in Fig. 1 are presented
as error bars in Figs. 4–6 and represent the experimental average range in
which model predictions are considered to reﬂect cellular response.
Statistical analysis
A one-way analysis of variance was performed on bone and BMSC dose-
response experiments using SYSTAT 11 (Systat Software, Point Richmond,
CA). Multiple comparisons were performed using a Tukey-Kramer Honestly
Signiﬁcant Difference test. Statistical signiﬁcance was attained at p # 0.03.
Analytical methods
Surface binding events
The methodology employed in the model presented here is reviewed
elsewhere (54). The three binding pathways leading to the formation of a
2:2:2 signaling complex induced by 18 kDa FGF2 are described in Fig. 3 a.
These pathways are evaluated individually to assess their potential to con-
tribute to ternary complex formation. Model terms and related equations are
listed in Tables 2 and 3. Certain assumptions have been included in this
model. The possibility of different afﬁnities of FGF2 to the various high
afﬁnity receptors on the cell surface has been ignored. Instead, a general
FGFR is assumed. Although the relative FGF2 induced mitogenic activity of
the major splice variants known for FGFRs on BaF3 cells have not been
found to be equal (55), the possibility of differences in kinetic binding con-
stants for the various FGFRs exists; this model compares its predictions to
experimental data that has been normalized with respect to each data set.
This allowed us to exploit common patterns observed in FGF2 induced
mitogenesis in osteoblastic cells without constraining our evaluation to a
particular cell type or receptor expressed. This also allowed us to simplify
model estimations by ignoring potential changes in receptor expression or
mitogenic response within a given cell type due to maturation (56–58) or
stage of differentiation (59). FGF2 is known to enter cells through both
HSPG- and FGFR-mediated pathways (60). The only complexes that are
assumed to be internalized are CsHF (FGF2 bound to HSPG) and the ternary
signaling complexCsT. Internalization of FGF2 bound to FGFR (CsRF) alone
is ignored as it would be subjected to heat, pH, and proteolytic degradation
without protection from HSPGs (61,62). In addition, FGF2 has a decreased
probability for internalization in the absence of HSPGs and has been found
to stimulate mitogenesis in HSPG deﬁcient cells only at nonphysiologic
supersaturated concentrations (30). While we do not consider HSPG-bound
FGF2 to contribute to mitogenic signaling, it does contribute to the depletion
of ligand in the surrounding media as well as intracellular levels of FGF2.
For these reasons, equations for the binding and subsequent processing of
FGF2 bound HSPGs (CsHF, CiHF) were included in all models. While it is
likely that multiple ligands will bind to the heparan sulfate chains on HSPGs
as observed with a single heparin (63–65), we assume only one FGF2 to
bind to each HSPG for simplicity. Fluid phase FGF2 uptake (66) and the
possibility of internalization of the intermediate surface complex (CsI) are
ignored. Only one pathway for the formation of ternary complexes from
intermediate complexes is evaluated across all models for simplicity.
The number of FGFRs and HSPGs we employed in this model is shown
in Table 4 (67). These values fall within reported ranges for receptor pop-
ulations on cell surfaces (FGFRs, 0.2–5 3 104 sites/cell; HSPGs, 0.5–2 3
106 sites/cell (68)). Due to high local concentrations of HSPGs and their high
afﬁnity to FGFRs, it has been suggested that HSPGs may bind FGFRs
constitutively (69). To accommodate this, the initial conditions in pathway C
TABLE 1 Rabbit bone and BMSC proliferative dose response
FGF2 (ng/ml) 0 0.01 0.1 1 10 100
Rabbit bone 114 3 103 125 3 103 174 3 103 370 3 103* 464 3 103y 352 3 103*
6SD 6 20 3 103 6 100 3 103 6 17 3 103 6 19 3 103 6 250 3 103 6 83 3 103
Rabbit BMSC 55 3 103 57 3 103 79 3 103 85 3 103z 140 3 103§ 104 3 103z
6SD 6 6.0 3 103 6 9 3 103 6 9 3 103 6 9 3 103 6 14 3 103 6 16 3 103
Cells were seeded in 24 well plates at 1 3 104 cells/cm2. Values presented are cell numbers determined through Coulter Counting 6 SD after ﬁve days of
exposure to FGF2, seven days of cell culture (n ¼ 4).
*Signiﬁcantly different than 0 and 0.01 ng/ml doses (p # 0.006).
ySigniﬁcantly different than all doses (p # 0.03).
zSigniﬁcantly different than 0 and 0.01 ng/ml doses (p # 0.03).
§Signiﬁcantly different than all doses (p # 0.004).
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were set so that all of the FGFRs were bound to HSPGs at time t¼ 0 (Rs¼ 0,
Hs ¼ 166,500; CsHR ¼ 21,500). No whole-cell kinetic constant values could
be found in the literature describing the association of FGFRs and native
HSPGs. Instead, we took binding constant data for heparin-FGFR1 IIIc (69)
and multiplied by the cell density/Avogadro’s number (r/Nav, see Table 4) to
be consistent with the units in the model equations. Model parameters that
were not available in the literature including those describing certain surface
binding events (k1A, k2A, k1B, k2B, k3, k4), surface release rates (krelCHF, krelH),
and HSPG internalization rate (kiH) were estimated based on best ﬁt to the
experimental average bone cell proliferation data. A parametric analysis was
performed on these rate constants to determine the range of their impact on
model predicted outcomes. Constants sensitive to alterations were chosen
based on ﬁt to experimental proliferation data as well as the strength of their
correlation (r) to the experimental average determined in a correlation
analysis. For parameters that did not have a major impact on model
predictions, the fastest values were chosen based on evidence of stability (no
change in model predictions), ﬁt within experimental average range and
correlation. This form of analysis was also performed on the forward and
reverse rate constants for in Model C for the binding between HSPG and
FGFR (kfC, kRC).
A lumped rate constant has been used for receptor synthesis based on
epidermal growth-factor receptor synthesis (70). This constant was multi-
plied by the proportion of FGFR/HSPG (11:89) expressed on the surface
of human bone cells (67). The cell density value (r ¼ 107 cells/L) was based
on the estimated experimental conditions of referenced articles as well as
experiments performed in our laboratory. Ligand recycling is assumed
negligible in this model (60). Receptor recycling is also ignored since the
recovery of downregulated FGFRs occurs through receptor synthesis, not
recycling (71). Finally, internalization of FGF2, through both receptor-
mediated (72) and HSPG-mediated (66,73) events, are independent of
clathrin-coated pits. Although HSPG-mediated FGF2 internalization has
been reported to occur through both noncoated ﬂask-shaped invaginations
and caveolae (66), no direct distinction in internalization kinetic rate
constants for the speciﬁc modes of internalization could be found in the
literature. General internalization rates for CsHF (kiCHF) and CsT (kicT) are
used.
Internalization and secretion into media of a fraction of cell surface
HSPGs is a normal part of cellular HSPG metabolism (74,75). Although no
kinetic rate constants were available in the literature for the involvement of
these processes in FGF2metabolism, we assume them to be a relevant aspect
of FGF2 metabolism in cells based on the experimental values of FGF2
intracellular localization and excretion into the media by vascular smooth
muscle cells (VSMCs) (76). Rate constants for the release of HSPG and
FGF2-bound HSPG into the media (krelH, krelCHF) and internalization of
HSPG (kiH) were estimated and were included in our equations (Table 4) for
surface bound HSPGs both with and without bound FGF2.
After comparing model predictions to experimental results, there
appeared to be multistep processes involved in the internalization and
release of surface HSPGs and HSPG-FGF2 complexes (Hs, CsHF), as well as
in HSPG and FGF2 low molecular weight (HLMW, CLMW) fragment forma-
tion that were not accounted for by the linear kinetic constants describing
those processes (kiCHF, kiH, krelH, krelCHF, kLMW). The step functions I(t), R(t),
and L(t) (Table 3) were added to account for these potential processes and ﬁt
model predictions to experimental results.
Intracellular processing and media released products
The rate constants used in the intracellular processing component of our
model were collected from VSMCs and describe FGF2 complex internal-
ization and degradation, and FGF2 LMW fragment formation and degra-
dation (76) (Fig. 3 b). We converted their data into a percentage of maximum
media excreted products. We relate the experimentally determined media
excreted and release products to our excreted FGF2 complexes (Cm) re-
sulting from release of surface HSPG-bound FGF2 (CsHF) into the media
(krelCHF), degraded intracellular ternary complexes (CiT values) and intra-
cellular FGF2-HSPG complexes (CiHF values), and degraded low molecular
weight FGF2 fragments (CLMW values). Intracellular processing in all of the
binding orders evaluated in this article is assumed to be the same.
The metabolic processing of HSPGs is also considered in this model.
Data was taken from 80 min pulse-chase experiments using rat ovarian
granulose cells (74). The time of the radioactive pulse was used to target
details regarding the proteoglycan degradation process. HSPG metabolism
in Chinese hamster ovarian (CHO) cells as determined by 1 h pulse-chase
experiments was found to be similar in these cells both with and without
exposure to 5 ng/ml FGF2 (77). Results are displayed from these experi-
ments for cells exposed to 5 ng/ml FGF2.
For HSPG metabolism, we relate the experimentally determined media
HSPG concentration to our excreted HSPG products (Hm) resulting from
release of surface HSPGs (Hs) and HSPG bound FGF2 (CsHF) into the media
(krelH, krelCHF), degraded intracellular HSPGs (Hi), ternary complexes (CiT),
and intracellular FGF2-HSPG complexes (CiHF), and degraded low molec-
ular weight fragments (HLMW, CLMW). Cell surface HPSGs are related
to unbound cell surface HSPGs (Hs) and bound initial, intermediate, and
ternary complexes involving HSPGs that have not been internalized (CsHF,
CsHR, CsI, CsT).
Fractions were used to divide the internalized complexes into those sent
immediately down a degradation pathway (fH, fCHF, fCT) and the amount that
remained in the cell longer either to form LMW species (1-fH, 1-fCHF) before
degradation or be sent to the nucleus before LMW formation and deg-
radation (1-fCT). Only ternary complexes associated with stimulation of
FIGURE 1 Plot of osteoblastic cell proliferation data. Rat calvarie (*) (52)
and rat BMSC (h) (53) data were compiled from literature values. Rabbit
bone (n) and rabbit BMSC (1) data were obtained by the authors. The av-
erage of all data (—) was used to compare to model proliferation predictions.
TABLE 2 Model equation terms
Term Description
Rs Surface FGFR
Hs Surface HSPG
CsRF Surface FGF2-FGFR complexes
CsHF Surface FGF2-HSPG complexes
CsHR Surface FGFR-HSPG complexes
CsI Surface intermediate complexes (FGF2-HSPG-FGFR)
CsT Surface ternary complexes (CsI-CsI)
CiHF Intracellular FGF2-HSPG complexes
Hi Intracellular HSPG
CiT Intracellular ternary complexes
CLMW Low molecular weight FGF2 fragments (from CiT, CiHF)
HLMW Low molecular weight HSPG fragments (from Hi)
Cm FGF2 degradation products and surface released species
Hm HSPG degradation products and surface released species
I(t) Step function used to alter Hs and CsHF internalization
R(t) Step function used to alter Hs and CsHF release
L(t) Step function used to alter CLMW and HLMW release
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mitogenic response (CiT) are assumed to be translocated to the nucleus. The
intracellular destination of endocytosed FGF2/HSPG complexes (CiHF) is
different than that of complexes with FGF2/HSPG/FGFRs and has been
shown to localize in the nucleus only at very high, nonphysiologic con-
centrations of FGF2 (2.5 mg/ml) (77). There were no literature values for
the kinetic rate constants describing nuclear translocation. Accordingly, we
assumed the kinetic constant allocated describing LMW fragment formation
and degradation would be inclusive of translocation to and from the nucleus.
Sperinde and Nugent (76) note that the rate constant they determined
describing the degradation of LMW FGF2 fragments (kLMWd) was an
observed rate constant, not a fundamental mass action rate constant. Since
observed rate constants are usually a function of several fundamental rate
constants (78), it is conceivable that nuclear translocation is accounted for at
least by kLMWd.
Converting model data to proliferative response
To compare this model to cellular proliferative response data, a correlation
had to be drawn between the number of ternary signaling complexes formed
and percentage of maximum cellular response. Fannon and Nugent (30)
found a near linear relationship between predicted receptor occupancy and
DNA synthesis in both normal and heparan sulfate deﬁcient Balb/c3T3
ﬁbroblasts (r ¼ 0.98). Assuming this direct correlation with respect to our
model, we multiplied our concentration dependent average percentage of
maximum proliferative response of bone and bone marrow derived rat and
rabbit osteoblastic cells (Fig. 1) by the number of FGF receptors found on
human bone cells (21,500 #/cell) (67), to develop a universal conversion to
quantify the total occupied receptor data given by the models in terms of
percentage of maximum osteoblastic proliferative response,
%MaximumResponse ¼ 4:65123 ðTORÞ; (1)
where TOR is the Total Occupied Receptors 3 103 (R2 ¼ 1) described in
Fig. 2.
In this model, mitogenic response is assumed to be a function of inter-
nalized ternary signaling complexes. Mathcad 11 (Mathsoft Engineering
& Education, Cambridge, MA) was used to solve the systems of differential
equations presented in this article. The routine rkadapt, which executes a
Runge-Kutta method of integration using a nonuniform step size, was used
to reach a solution. Simulations were run for a period of 600 min. Since
maximal FGFR binding has been observed in Balb/c3T3 cells in ;180 min
(79) and downregulation of HSPGs has been observed in fetal bovine aortic
endothelial GM 7373 cells after 6–8 h (80), this was considered more than
sufﬁcient time to observe signaling complex formation. Output data from the
model provided the number of CT values located on the cell surface and
internally. However, since 600 min is not enough time for all of the occupied
receptors that have formed ternary complexes to be internalized, surface and
internal CT values (CsT and CiT) were used to evaluate a cell’s downstream
proliferative response.
RESULTS AND DISCUSSION
The high afﬁnity binding observed with FGFRs make them
potential candidates for the initial binding event in the
TABLE 3 Model equations
Model A
Surface species dRs/dt ¼ kfALRs 1 kRACsRF 1 0.11 ks
dHs/dt ¼ k1ACsRFHs 1 k2ACsI 1 0.89 ks  kfBLHs 1 kRBCsHF  kiHHsI(t)  krelHHsR(t)
dCsRF/dt ¼ kfALRs  kRACsRF  k1ACsRFHs 1 k2ACsI
dCsHF/dt ¼ kfBLHs  kRBCsHF  kiCHFCsHFI(t)  krelCHFCsHFR(t)
dCsI=dt ¼ k1ACsRFHs  k2ACsI  k3C2sI12k4CsT
dCsT=dt ¼ k3C2sI  2k4CsT  kiCTCsTIðtÞ
(Nav/r)dL/dt ¼ kfALRs 1 kRACsRF  kfBLHs 1 kRBCsHF
Model B
Surface species dHs/dt ¼ kfBLHs 1 kRBCsHF 1 0.89 ks  kiHHsI(t)  krelHHsR(t)
dRs/dt ¼ k1BCsHFRs 1 k2BCsI 1 0.11 ks
dCsHF/dt ¼ kfBLHs  kRBCsHF  k1BCsHFRs 1 k2BCsI  kiCHFCsHFI(t)  krelCHFCsHFR(t)
dCsI=dt ¼ k1BCsHFRs  k2BCsI  k3C2sI12k4CsT
dCsT=dt ¼ k3C2sI  2k4CsT  kiCTCsTIðtÞ
(Nav/r)dL/dt ¼ kfBLHs 1 kRBCsHF
Model C
Surface species dHs/dt ¼ kfCRsHs 1 kRCCsHR 1 0.89 kskfBLHs 1 kRBCsHF  kiHHsI(t)  krelHHsR(t)
dRs/dt ¼ kfCRsHs 1 kRCCsHR 1 0.11 ks
dCsHR/dt ¼ kfCRsHs  kRCCsHRk1CLCsHR 1 k2CCsI
dCsHF/dt ¼ kfBLHs  kRBCsHF  kiCHFCsHFI(t)  krelCHFCsHFR(t)
dCsI=dt ¼ k1CLCsHR  k2CCsI  k3C2sI12k4CsT
dCsT=dt ¼ k3C2sI  2k4CsT  kiCTCsTIðtÞ
(Nav/r)dL/dt ¼ k1CLCsHR 1 k2CCsI  kfBLHs 1 kRBCsHF
Models A, B, and C
Intracellular species dCiHF/dt ¼ kiCHFCsHFI(t)  kLMW(1fCHF)CiHFL(t)  kdegfCHFCiHF
dCiT/dt ¼ kiCTCsTI(t)  kLMW(1fCT)CiTL(t)  kdegfCTCiT
dHi/dt ¼ kiHHsI(t)  kLMW(1fH)HiL(t)  kdegfHHi
dCLMW/dt ¼ kLMW(1fCHF)CiHFL(t) 1 kLMW(1fCT)CiTL(t)  kLMWdCLMW
dHLMW/dt ¼ kLMW(1fH)HiL(t)  kLMWdHLMW
dCm/dt ¼ kdegfCHFCiHF 1 kdegfCTCiT 1 kLMWdCLMW 1 krelCHFCsHFR(t)
dHm/dt ¼ kdegfHHi 1 kLMWdHLMW 1 krelHHsR(t)
Step FNs I(t): 0.4 if t # 120, 6 3 104 t otherwise
R(t): 10 if t # 120, 1 otherwise
L(t): 3 if t # 400, 7 otherwise
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formation of a ternary complex. Despite a lower afﬁnity, the
increased proportion of HSPG/FGFR make HSPGs potential
candidates for the initial site of FGF2 binding as well.
Combined with their abundance, the relatively high afﬁnity
between HSPGs and FGFR makes constitutive complexes
between the two an additional potential candidate for the site
of initial FGF2 attachment (69). All three of these modes of
initial binding and the implications of the kinetic compo-
nents used to predict proliferation were evaluated. Each of
the three binding pathways is depicted in Fig. 3 a. To predict
proliferative response and intracellular FGF2 processing, a
set of ordinary differential equations was used to describe
each event in each of the models in Fig. 3. Model predictions
were compared to an average percentage of maximum
osteoblastic cell response (Fig. 1). While the extent of cell
proliferation in terms of cell number can vary across cell
types as seen in data collected in our laboratory (Table 1), the
pattern of proliferative dose response to FGF2 can be similar
(Fig. 1). Utilizing a percentage of maximum response allowed
us to normalize data collected in our lab and from the
literature (52,53) and exploit this pattern of response ex-
hibited across two cell types (bone and BMSCs) in two
species (rabbit and rat) in an effort to compare our model
predictions to a generalized physical cell response (Fig. 2).
Error bars on experimental average data points seen in Figs.
4–6 represent the standard deviation between data points in
Fig. 1 and represent a general range of proliferative response
at each dose of FGF2 as seen within the cell types and species
examined in this analysis. The model terms, parameters, and
equations can be found in Tables 2–4, respectively.
Available literature kinetic rate values for the formation of
intermediate complexes between heparin and CsRF (FGFR/
FGF2 complexes) and FGFR and CsHF (HSPG/FGF2 com-
plexes) were performed using surface plasmon resonance with
neoproteoglycan and FGF2 sensor chips (17). These results
were inconsistent with whole-cell data for FGF2-FGFR bind-
ing (79,81) and with data showing higher FGF2 afﬁnity for the
FGFR compared to HSPG (67,79). The differences between
the sensor chip’s immobilized components and a cell culture or
in vivo environment could be the cause of these discrepancies.
TABLE 4 Model parameters
Parameter Description Value Ref.
Surface parameters
kfA Forward rate constant, FGF2 binding to FGFR 2.5 3 10
8 M1 min1 (79)
kRA Reverse rate constant, FGF2 binding to FGFR 4.8 3 10
2 min1 (79)
kfB Forward rate constant, FGF2 binding to HSPG 0.9 3 10
8 M1 min1 (79)
kRB Reverse rate constant, FGF2 binding to HSPG 6.8 3 10
2 min1 (79)
kfC Forward rate constant, HSPG binding to FGFR 1.89 3 10
10 (#/cell)1 min1 (69)
kfC* Model estimated forward rate constant, HSPG binding to FGFR 5.67 3 10
7 (#/cell)1 min1 Text
kRC Reverse rate constant, HSPG binding to FGFR 7.2 3 10
1 min1 (69)
kRC* Model estimated reverse rate constant, HSPG binding to FGFR 1 3 10
3 min1 Text
k1A Forward rate constant, FGF2-FGFR (CsRF) binding to HSPG 3.87 3 10
6 (#/cell)1 min1 Text
k2A Reverse rate constant, FGF2-FGFR (CsRF) binding to HSPG 1.26 3 10
2 min1 Text
k1B Forward rate constant, FGF2-HSPG (CsHF) binding to FGFR 3.60 3 10
6 (#/cell)1 min1 Text
k2B Reverse rate constant, FGF2-HSPG (CsHF) to FGFR 1.0 3 10
4 min1 Text
k1C Forward rate constant, FGF2 binding to HSPG-FGFR (CsHR) 2.27 3 10
8 M1 min1 (79)
k2C Reverse rate constant, FGF2 binding to HSPG-FGFR (CsHR) 3.0 3 10
3 min1 (79)
k3 Forward rate constant, intermediate complex binding (CsI to CsI) 1 3 10
1 (#/cell)1 min1 Text
k4 Reverse rate constant, intermediate complex binding (CsI to CsI) 1 3 10
7 min1 Text
ks General receptor synthesis rate 130 (#/cell) min
1 (70)
krelCHF Release of surface FGF2-HSPG complexes (CsHF) 6.25 3 10
4 min1 Text
krelH Release of surface HSPGs (Hs) 5.84 3 10
4 min1 Text
r Cell density 107 cell/L Text
Nav Avogadro’s number 6.02 3 10
23 #/mol
Hs Number of surface HSPGs 188,000 #/cell (67)
Rs Number of surface FGFRs 21,500 #/cell (67)
Internalization parameters
kiCHF Surface FGF2-HSPG complex (CsHF) internalization rate constant 0.0048 min
1 (76)
kiCT Surface ternary complex (CsT) internalization rate constant 0.012 min
1 (76)
kiH surface HSPG (Hs) internalization rate constant 0.0317 min
1 Text
Intracellular
trafﬁcking parameters
kLMW Formation of LMW weight intracellular FGF2 fragments (CLMW) 2.38 3 10
3 min1 (76)
kLMWd Degradation of LMW weight intracellular FGF2 fragments (CLMW) 6.67 3 10
4 min1 (76)
kdeg FGF2 degradation rate constant 7.5 3 10
3 min1 (76)
fCHF Fraction of intracellular CiHF sent on an immediate degradation path 0.6 Text
fCT Fraction of intracellular CiT sent on an immediate degradation path 0.6 Text
fH Fraction of intracellular Hi sent on an immediate degradation path 1 Text
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Instead, we estimated the intermediate binding rate constants
for models A and B (k1A and k1B) by ﬁtting the proliferation
predictions to the experimental data. After converting the
units by multiplying by Nav/r, one can see that these values
(2.33 3 1011 and 2.17 3 1011 M1 min1 for k1A and k1B,
respectively) are considerably faster than the initial forward
rate constants, of the order of 108 M1 min1 (Table 4), for
either model. To test whether or not the constants used could
be of physiological relevance, we performed a simple cal-
culation to determine whether the rate constants used would
allow enough time for a given receptor to laterally diffuse
to its constituent(s) through the plasma membrane. We
assigned a hemispherical shape to the average osteoblast
with an average cell volume of 910 mm3 (82) giving each an
average surface area of 227 mm2. If FGFRs and HSPGs were
evenly distributed throughout the surface, there would be an
FGFR every 0.011 mm2 and a HSPG every 0.0012 mm2.
Lateral diffusion rate constants of the order of 109–1010
cm2/s (83–85) have been measured for various receptors on
ﬁbroblast cells using ﬂuorescence recovery after photo-
bleaching. Since such analysis compiles averages of motion
and is not sensitive to the effects of anomalous diffusion (86)
that can occur due to factors such as cytoskeletal obstacles
(87) or binding (88), we will assume a slower general surface
receptor diffusivity coefﬁcient (Ds ¼ 1011 cm2/s) to test the
relevance of the estimated intermediate rate constants. To
determine the theoretical area, Ar, in which it would be
possible for each receptor to travel during a binding event,
we used the relationshipDs/(rsk) Ar, where rs is the number
of surface FGFRs or HSPG receptors, and k is the forward
rate constant for CsRF to HSPG or CsHF to FGFR (k1A or k1B).
One can see that depending on which receptor diffuses to
form the intermediate ternary complex, it would be able to
travel within a 0.082–0.775 mm2 area per binding event.
This would be a large enough area for any of the receptors
to encounter its counterpart, even if the surface receptor
diffusivity coefﬁcient was an order-of-magnitude slower
(Ds ¼ 1012 cm2/s), at a minimum establishing plausibility
to the model estimated intermediate rate constants. The re-
verse rate constants were chosen to best ﬁt average experi-
mental proliferation predictions with a maximum correlation
coefﬁcient.
The predicted bone cell proliferation for the binding orders
described in Fig. 3 a are plotted in Fig. 4. Model C, in which
FGFRs are constitutively bound to HSPGs, predicts consid-
erably lower proliferative responses at all doses. Converting
the units of the initial forward rate constant in Model C by
multiplying by Nav/r, the value of kfc is 1.14 3 10
7 M1
min1. This is slower than the initial forward rate constants
for both Models A and B, which were measured on whole
cells (kfA ¼ 2.5 3 108 M1 min1 and kfB ¼ 9 3 107 M1
min1). Conversely, the reverse rate constant kRC ¼ 7.2 3
101 min1 is faster than the initial reverse binding rate
constants forModels A and B (kRA¼ 4.83 102min1, kRB¼
6.8 3 102 min1). The experiments in which these rate
constants were measured were performed with the soluble
ectodomains of FGFRs and heparin immobilized on micro-
titer plates (69). If prebound complexes between HSPGs and
FGFRs are of any consequence, it is conceivable that the
afﬁnity of these receptors for each other could be greater than
that of FGF2 to either receptor. It is also possible that the
reverse binding rate constants for these receptors could be
slower when the receptors are bound to a cell surface as they
are in vitro. By optimizing the forward and reverse binding
constants for Model C (using kfC* ¼ 5.67 6 107 (#/cell)1
min1, kRC* ¼1 3 103 min1), we were able to signiﬁ-
cantly increase the model predicted proliferative response
presented in Fig. 4 as Model C* (indicating the use of kfc*
and kRC* in Model C). If constitutively bound HSPG/FGFR
complexes do in fact play a role in FGF2 induced prolifer-
ation, this result indicates that perhaps HSPG/FGFR com-
plexes form more quickly and are more stable on in vitro cell
surfaces than in the experimental conditions listed above.
However, if the experimentally estimated rate constants do
reﬂect whole-cell kinetic rate constants, then it is not likely
that HSPG/FGFR complexes on cell surfaces are a main
constituent in the formation of ternary proliferative signaling
complexes.
Comparison of experimental and model proliferation results
None of the proposed model binding pathways were suc-
cessful at predicting bone cell proliferation within the ex-
perimental average range at a low concentration of FGF2
(0.01 ng/ml). All experimental proliferation data collected in
our lab and by other authors (52,53) were conducted in the
presence of serum. Since there are many growth factors in
serum (89) including FGF2 (90), this could reﬂect an
additional concentration of FGF2 present under experimen-
tal conditions and not accounted for by the model. Alterna-
tively, the model conversion system may not be sensitive
FIGURE 2 Correlation between total occupied receptors and percentage of
maximum bone cell proliferative response. Average osteoblastic cell pro-
liferative response data was plotted in conjunctionwith receptor occupancy to
create a relationship used to convertmodel output to proliferative response (%
Maximum Response ¼ 4.65123 (TOR)).
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enough at low concentrations of FGF2 or the equations used
in the models may not accurately represent FGF2 induced
bone cell proliferation events at small doses of FGF2.
Beyond very low concentrations, the proliferation predic-
tions for Models A and B both lay within the upper and lower
limits of the experimental proliferation data for rat and rabbit
bone and bone marrow stromal cells (Fig. 1). This makes it
impossible to unequivocally identify either as the model for
signaling complex formation. The average of the two pro-
vides a good ﬁt to the experimental data, indicating that a
combination of the two could possibly occur in vitro (data
not shown). Utilizing the optimized forward and reverse
binding constants (kfC* and kRC*) in Model C* greatly
improved proliferation predictions for this binding order.
Again, all of the data points, except at 0.01 ng/ml FGF2, fell
within the upper and lower limits of the experimental pro-
liferation constraints, making this model also a potential
candidate for proliferative signal complex formation.
Parametric analyses
Estimated model parameters describing surface binding events
that were not available in the literature (k1A, k2A, k1B, k2B, k3,
k4, krelH, krelCHF, kiH) were subjected to a parametric analysis
FIGURE 3 (a) A schematic representation of the potential binding
pathways involved in the piecewise assemblage of a proliferative signaling
complex of FGF2/HSPG/FGFR in a 2:2:2 stoichiometry. In all three path-
ways, binding order of the constituents vary in the initial and intermediate
binding steps. In Pathway A, FGF2 (L) binds to FGFR (Rs), forming CsRF,
which binds to an HSPG (Hs), to form the intermediate complex (CsI). In
Pathway B, FGF2 (L) binds to an HSPG (Hs) forming CsHF, which can be
internalized (kiCHF) or released into the medium (krelCHF). CsHF then binds to
an FGFR (Rs) to form CsI. In Pathway C, the receptors (Rs and Hs) bind
initially to form CsHR, then FGF2 (L) binds to that complex to form the
intermediate complex CsI. The tertiary binding event is the same in all
pathways—two intermediate complexes bind to form the ternary signaling
complex (CsT), which can be internalized (kicT). Cell surface HSPGs can also
be internalized (kiH) or released into the surrounding medium (krelH). (b) The
potential intracellular processing events of endocytosed FGF2. The growth
factor can enter the cell when bound to HSPGs (CsHF) or when part of the
ternary signaling complex (CsT). Surface HSPG (Hs) and HSPG-bound
FGF2 (CsHF) can also be released into the surrounding medium without
being internalized (krelH, krelCHF). Once internalized, the 18 kDa growth
factor is cleaved into a 16 kDa form (107). FGF2 in the ternary complex can
be transported with its receptors to the nucleus for further signaling. Some
internalized (76,103) FGF2 is degraded into low molecular weight
fragments (CLMW) before further degradation and subsequent release for
the cell. Internalized HSPG (Hi) can also be degraded into low molecular
weight fragments (HLMW) before further degradation and subsequent release
for the cell.
FIGURE 4 Comparison of the dose response proliferation predictions of
all models (A–C) to the experimental average (d). Using a slower
association and dissociation value for CsHR complexes then measured
experimentally (kfc* and krC*) improved Model C proliferation predictions.
These results are displayed in Model C*. Predictions are displayed as Model
A (—), Model B (– –), Model C (– - - –), and Model C* (—-). Error bars on
the experimental average data points represent the standard deviation
between experimentally measured proliferation dose responses of rabbit and
rat bone and BMSC presented in Fig. 1. These error bars represent the
experimental range within which model predictions are considered to reﬂect
actual cellular response.
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to evaluate their impact on model predicted outcomes. All
rate constants were initially estimated based on a ﬁt to the
experimental proliferation data. Subsequent analysis in-
volved evaluating predictions over a range of 1/1000th to
1000 times the initial estimate. If parameters demonstrated a
sensitivity to alteration based on a comparison to model
proliferation predictions and correlation coefﬁcient value,
further scrutiny was applied over a smaller range of values to
maximize correlation while remaining within the average
experimental proliferation range. Rate constants that were
common to all models (k3, k4, krelH, krelCHF, kiH) were
optimized in Model A. While optimized values were utilized
in all other models, they were also subjected to the above-
outlined parametric analysis to verify a consistent best ﬁt to
the proliferation data.
For Model A, all parameters evaluated (k1A, k2A, k3, k4,
krelH, krelCHF, kiH) were sensitive over a range of at least
1022–100 times initial estimates except for k4. In some cases,
this range was greater and the degree to which perturbations
in values impacted predictions varied. An example of this
analysis for k1A is shown in Fig. 5, a and b. The tertiary
reverse rate constant k4 was not very sensitive over a range of
1023–1000 times the initial estimate (1 3 1027 min21).
Values faster than or equal to 1023 min21 greatly reduced
proliferation predictions, and values equal to or slower than
1027 min21 did not alter prediction at all. After analysis, this
rate constant was chosen to be k4¼ 13 1027 min21 because
it was the fastest rate at which stability was observed and
marginally increased the ﬁt of model proliferation predic-
tions to the experimental average range. After all optimiza-
tions, the ﬁnal model correlation to the experimental average
for Model A was r ¼ 0.9863. In Model B, all rate constants
evaluated (k1B, k2B, k3, k4, krelH, krelCHF, kiH) were sensitive
over a range of at least 1022–10 times initial estimates except
for k2B and k4. Again, this range was greater in some cases,
and the degree to which perturbations in values affected
predictions varied. The selection of k4 is outlined above. For
the intermediate reverse rate constant k2B, correlation and
prediction values did not change much over the broad range
of 1023–1000 times the initial estimate. However, these
values were identical from 1021 to 1023 times the initial
estimate and had a slightly higher correlation. A value of
1021 times the initial estimate was chosen for the model
(k2B ¼ 1.0 3 1024 min21) because it was the fastest in this
range. The ﬁnal model correlation to the experimental aver-
age for Model B was r ¼ 0.9658.
In Model C, proliferation predictions were well below the
experimental range. In this case, a parametric analysis was
performed for values found in the literature for HSPG/FGFR
binding (kfC, kRC). Both values were sensitive over a range of
1023–1000 times the literature-measured values (see Table
4). These values were optimized to ﬁt the experimental data
(r ¼ 0.9801). A parametric analysis was performed on the
remaining constants that were not available in the literature
(k3, k4, krelH, krelCHF, kiH). None of the values were sensitive
over a range of 1023–1000 times the optimized values
determined from the analysis in Model A. This is likely due
to the initial conditions in Model C* that stipulate all of the
FGFRs are prebound to HSPG before exposure to FGF2.
Impact of FGF2 binding kinetics on model
proliferation predictions
The FGF2 binding rate constants utilized for the initial
binding events in Models A and B (kfA, kRA; kfB, kRB) and the
intermediate binding event for Model C* (k1C, k2C) were
measured on intact cells at a concentration of 0.55 nM FGF2
at 4C to inhibit internalization (79). However, low temper-
ature evaluation has been shown to signiﬁcantly decrease the
rates of epidermal growth factor receptor dimerization and its
dephosphorylation (91). Comparable values using the same
FGF2 concentration measured in vascular smooth muscle
cells (VSMCs) at 37C were both faster (kfA ¼ 4.2 3 108
M21 min21, kRA ¼ 0.79 min21, k2C ¼ 0.038 min21) and
slower (k1C¼ 1.23 108 M21 min21) than values used in this
article (81). While these differences could be a function of
temperature, they could also be of the cell system used as
FIGURE 5 (a) An example of the parametric analyses performed on
surface binding constants not found in the literature. This example is for the
forward binding of FGF2-FGFR (CsRF) to HSPG (k1A) for Model A. This
analysis was performed over a range of 103–102 times the initial rate
constant estimate, which was along the order of 106 (#/cell)1 min1. Panel
a shows model predicted bone cell proliferative response with 4.33 109#
k1A# 4.33 10
4. (b) Shows model predictions over a range of 2.583 106
# k1A # 4.73 3 10
6. A value of 3.87 3 106 was chosen to use in this
model based on a correlation analysis between model predictions and the
experimental average proliferative dose response of osteoblastic cells (d)
(r ¼ 0.9863).
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well as the differences in rending the cells HSPG deﬁcient
(chlorate versus heparinase I treatment). Such differences
merit investigation. We evaluated the potential impact of
both higher and lower FGF2 binding rate constants in all
three models. In all models, proliferation predictions were
sensitive to increases and decreases in FGF2 binding rate
(data not shown). Beyond the potential for physiologic
variability in the binding rate constants due to temperature,
FGF2 is also known to bind to all FGFRs but with varying
afﬁnities (26,55), and HSPGs expressed on different cells
can have different abilities to mediate FGFR signaling (92).
All of these factors could potentially have a great impact on
in vitro cellular response. This model is proposed to evaluate
potential binding mechanisms for a generalized average of
bone cell proliferation. We acknowledge that such general-
izations have implications on predicted response. As more
information becomes available within speciﬁc cell types
(including receptor numbers and types and associated rate
constants), this model could be used to obtain speciﬁc
tangible information regarding binding mechanisms.
Impact of HSPGs and FGFRs on model
proliferation predictions
HSPGs might act as dynamic regulators of HS binding
proteins, depending on cell environment or status (93). The
impact of the ratio of HSPGs to FGFRs is demonstrated in
Model A in Fig. 6 a. Increasing the ratio of HSPG:FGFR
from the experimentally measured value for bone cells at
(8.7:1) (67) increased the predicted proliferative response.
Similarly, lowering the ratio decreased the predicted prolif-
erative response. This effect was also observed in Models B
and C*, but was not as pronounced in Model C* since all of
the FGFRs are assumed to be constitutively bound to HSPGs
before exposure to FGF2.
Subtle changes in heparan sulfate structure can have a
dramatic effect on biological activity (94). Speciﬁc FGF2
induced changes have been observed in the molecular
structure of heparan sulfate expressed on corneal endothelial
cells (95) and arterial smooth muscle cells (96). Cell density
has also been shown to impact HSPG expression, thus
affecting FGF2 induced corneal stromal ﬁbroblast mitogenic
response (97). Human bone cells are also known to express
different types of glycosaminoglycan chains on the same
proteoglycan core protein (98). HS saccharides can play both
an activating and inhibitory role in FGF2 binding to FGFRs
by controlling the type of saccharide motifs expressed on HS
chains (99). Such changes in HS structure or expression can
inﬂuence the number of HSPGs capable of participating in
FGF2-induced response and potential alterations in cell
response are highlighted in Fig. 6 a.
The number of FGFRs on the cell surface also affected pre-
dicted proliferative response. As receptor dimerization is
critical in FGF2 proliferative response, increases and decreases
in FGFRs increased and decreased growth predictions in all
FIGURE 6 (a) Evaluation of the impact of the ratio of HSPG:FGFR on
the proliferative effect of FGF2 on Model A. The experimentally measured
ratio of HSPG:FGFR on human bone cells is 8.7:1 (67). Predicted
proliferation response increased as the relative number of HSPGs to FGFRs
increased (evaluated here at 1:1, 4:1, 8.7:1, 13:1, and 18:1). These results are
compared to the experimental average dose response of osteoblastic cells
(d). A similar effect was observed in Model B. However, these results were
less dramatic in Model C* in which, even at a 1:1 ratio, all of the FGFRs are
already constitutively bound to HSPGs. (b) Evaluation of the effect of the
number of FGFRs on proliferative response in Model A. All models were
sensitive to increases and decreases in FGFR number. FGFR number was
evaluated at 0%, 25%, 50%, 100%, 150%, and 200% of value of FGFRs
measured on human bone cells (21,500 #/cell) (67). Model A is shown as an
example of this receptor’s impact. The results are compared to the
experimental average dose response of osteoblastic cells (d). (c) Evaluation
of the effect of cell density on proliferative response in Model B (r ¼ 106,
107, 108, 109, 1010 cell/L). The shift in the proliferation curve with decreased
predicted response at several concentrations is observed at very high cell
concentrations (r ¼ 109 and 1010 cell/L) and is similar in Models A–C*.
These results are compared to the experimental average dose response of
osteoblastic cells (d).
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models. The results for Model A are shown as an example in
Fig. 6 b; the effect was similar in all models.
Additional observations on proliferation predictions
The effect of cell density on proliferative response was
evaluated over a series of concentrations. Similar effects
were seen in all models. At concentrations of 106–108 cells/
L, proliferative response was similar. At highly dense con-
centrations (109–1010 cells/L), there is an obvious shift in the
predicted proliferative response curve and decreased re-
sponse at several concentrations of FGF2. This is not un-
expected, since ligand depletion at this cell density would
decrease ligand availability for signaling complex formation.
This effect was similar in all models; Model B is shown as an
example in Fig. 6 c. Another salient feature of proliferative
signaling illustrated in Fig. 6 c is the concept of thresholding
(100). By multiplying the molar FGF2 concentration at each
evaluated dose by Avogadro’s number divided by the cell
density (Nav/r), we can approximate the number of ligand
molecules available per cell. Although the model predicts
large-scale increases in cell growth starting before 0.1 ng/ml
for cell densities between 106 and 108 cells/L, such growth
does not begin to occur at densities of 109 and 1010 cells/L
until 0.1 and 1 ng/ml, respectively. For these cell densities
and ligand concentrations, this corresponds to ;3000 mole-
cules of FGF2 available per cell. While this threshold pro-
vides an explanation for the results observed mathematically,
its relevance in vitro would have to be explored experi-
mentally. Richardson and colleagues found FGF2 induced
rabbit stromal ﬁbroblasts cell proliferation to be cell density-
dependent, with maximum cell proliferation found at in-
termediate cell densities (97). They found a reduction in
FGF2 binding per cell as cell density increased. This density-
dependent binding reduction was found not to be a function
of reduced FGFR expression but rather modulation of
heparan sulfate proteoglycan expression (HSPGs). If HSPGs
act as regulators of FGF2 bioavailability (101), it is plausible
that the concept of thresholding in this system may not only
be a function of ligand concentration per cell in surrounding
media, but also the local binding environment in which the
allosteric interaction of HSPGs with FGFR control the
availability of FGF2 per cell.
Internal processing and media release of FGF2 and HSPG
Initial calculations for the intracellular fate of FGF2 in-
dicated that the linear rate constants obtained from the liter-
ature alone were not sufﬁcient to describe the experimentally
observed intracellular phenomenon at 0.28 nM FGF2 (76).
Since a considerable portion of the intracellular FGF2 was
bound to HSPG in the model (CsHF), we evaluated the
metabolism of HSPGs to ﬁnd clues to potentially resolve the
discrepancies between the predicted data and the experi-
mental data.
The cell surface HSPGs on rat ovarian granulosa cells are
either lost into the medium (30%, t1/2 ¼ 4 h) or internalized
(70%, t1/2 ¼ 4 h). HSPGs that are internalized either migrate
to lysosomes where they are rapidly degraded without
forming intermediate products (60%, t1/2 ¼ 30 min) or enter
into a longer processing pathway including proteolysis and
endoglycosidic degradation to one-third their original size in
endosomes (t1/2 ¼ 30 min), followed by endoglycosidic
degradation in lysosomes of one-quarter to one-ﬁfth their
original size (t1/2 ¼ 30–60 min), and then after a long half-
life (t1/2 ¼ 3–4 h), are rapidly degraded in lysosomes (74).
Similarly, medium secretion and two post-internalization
catabolic pathways have been observed for HSPGs on
Chinese Hamster Ovarian (CHO) cells and the distribution of
both cell and medium associated HSPGs were similar when
cells were exposed to 5 ng/ml (0.25 nM) FGF2 (77). In the
CHO cell study, the authors suggested that FGF2 remains in
complex with HSPGs and is transported through the same
endosomal pathway.
Since all CsT values are assumed to be internalized, the
possibility of a nonlinear, multistep process describing the
internalization of surface HSPG-FGF2 complexes (CsHF)
was investigated. The internalization rate for CsHF (kiCHF)
was multiplied by various step functions in an attempt to ﬁt
experimental data. The function I(t) (Table 3) was in good
agreement with experimental values of intracellular 18–16
kDa FGF2 (Fig. 7). However, the model underpredicted the
value of media excreted products at the early time points but
was successful at later time points (data not shown).
Examination of these results suggested the possibility of an
early burst or release of CsHF into the surrounding media at
the relatively high, nonphysiologic concentration at which
the experiment was preformed (0.28 nM FGF2). Such a
release could follow the normal HSPG metabolism described
above. Various step functions were tested in the model to
account for this release from the cell surface and R(t) (Table
3) was found to ﬁt the data. As illustrated in the experimen-
tally determined pathway for HSPG metabolism in granulose
cells, there are likely multiple steps involved in the pro-
cessing of HSPGs and FGF2-bound HSPGs. This was
evident in the lack of correlation to experimental data after
inclusion of the surface release step function R(t). Subse-
quently, the use of step functions to accommodate potential
multistep processes in the internalization of surface species
and the formation of LMW fragments were evaluated. All of
the FGF2 transported to the nucleus was assumed to be
shuttled from ternary complex fractions (fCT) opposed to
FGF2/HSPG complexes (fCHF). FGFRs are required for the
exogenous FGF2 stimulation of proliferation. Therefore, it is
assumed that complexes without FGFRs would not contrib-
ute to FGF2 induced mitogenic signaling. All of the models
used the same equations to represent the internal processing
of FGF2 (Table 3) and predicted similar results. Model A is
used as a representative in Fig. 7 a.
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While there was a good ﬁt between the experimental data
and model predicted results for the fate of intracellular
ligand, it was highly dependent upon the inclusion of the step
functions I(t), L(t), and R(t), indicating the potential
relevance of the involvement of multiple steps in the
internalization, LMW fragment formation, and medium
release of exogenously added FGF2 at relatively high doses
(0.28 nM). It must be noted that since the only kinetic and
experimental data available in the literature was performed
on VSMCs, direct correlations to osteoblastic cells could not
be drawn. Differences in FGFR and HSPG expression could
potentially correlate to differences in osteoblastic response.
Distinct kinetic differences in the metabolism of various
HSPGs (102) could also alter the relevance of the step
functions applied in this model.
Fig. 7 b shows data for media release and cell surface
presence of HSPGs. Model predictions are compared to ex-
perimentally measured results from rat ovarian granulose
cells (74) during 80 min pulse-chase experiments and Chinese
hamster ovarian (CHO) cells exposed to 5 ng/ml FGF2 as
determined by 1 h pulse-chase experiments (77). Experi-
mental data for osteoblasts was not available in the literature.
However, it is evident in Fig. 7 b that the model predictions
follow the pattern of response of HSPG metabolism in two
types of mesenchymal cells. Similarities in the response of
the granulose (not exposed to FGF2) and CHO cells (ex-
posed to FGF2) are evident. This is consistent with simi-
larities between the metabolic patterns observed in CHO
cells both with and without exposure to 5 ng/ml FGF2 and
provides evidence that HSPG metabolism is not altered at
relatively high concentrations of FGF2 (77). These exper-
imental results establish a framework through which both
the processing of HSPG- and FGFR-bound FGF2 can be
theoretically evaluated and has tremendous implications on
the bioavailability of growth factors through regulation by
HSPGs. Utilizing this framework of HSPG involvement in
FGF2 bioavailability in our model is supported by in vivo
evidence of HSPGs clearing exogenously added FGF2 in
Sprague-Dawley rats through cellular internalization and
catabolism without inducing the activation of FGFRs within
at least ﬁve organs in vivo (101). Finally, sustained presence
of a fraction of LMW FGF2 fragments observed within
several types of mesenchymal cells (80,81,103) could then
be accounted for by the normal metabolic processing of
HSPGs (74).
Relevance of other proliferative signaling
complex stoichiometries
While these models provide some insight into the potential
mechanisms of FGF2 induced proliferative signal complex
formation, it is important to continue this evaluation with
respect to the other potential stoichiometric conﬁgurations
that involve FGFR dimerization. Although substantial
information has been gained about the potential architecture
of the signaling complexes isolated using crystallographic
methods, neither conﬁguration was solved in a true physio-
logical state in which the heparan sulfate chains on the
proteoglycans involved are longer and receptors are bound to
the cell membrane (49). Accordingly, the physiological
relevance of the 2:2:2 (47) and 2:1:2 (48) models cannot be
conﬁrmed or excluded with certainty. A similar argument
holds for the alternate 1:1:2 model, solved using biophysical
analysis (50). While FGF2 dimers are linked to the prolif-
erative signaling complex (104,105), the identiﬁcation of two
receptor binding surfaces on FGF2 (106) presents the possi-
bility that under certain circumstances, FGFR dimerization
FIGURE 7 (a) Prediction of the intracellular processing of FGF2 for
Model A. Model predictions (dotted line) are compared to experimentally
measured results from VSMCs exposed to 0.28 nM FGF2 (76). Experi-
mental results are compared to their model counterparts and include
intracellular 18–16 kDa FGF2 (h) (compared to CiHF 1 CiT), intracellular
low molecular weight FGF2 ()) (compared to CLMW), and media excreted
products (*) (compared to Cm) are presented as a percentage of the
maximum of FGF2 excreted products. The step functions I(t), L(t), and R(t)
were used to compensate for differences observed in model predictedHs and
CsHF internalization and release into surrounding medium as well as LMW
fragment formation. The results are similar in all Models A–C*. (b)
Prediction of the metabolic processing of HSPGs for Model A. Model
predictions (solid line) are compared to experimentally measured results
from rat ovarian granulose cells (74) detailing HSPG cell surface
concentration (:) (compared to Hs 1 CsHF 1 CsHR 1 CsI 1 CsT) and
HSPG accumulation in the media (n) (compared to Hm 1 Cm) determined
during 80 min pulse-chase experiments. Results are also compared to HSPG
metabolism in Chinese hamster ovarian (CHO) cells exposed to 5 ng/ml
FGF2 as determined by 1 h pulse-chase experiments (77) (HSPG cell surface
concentration (n) and HSPG accumulation in the media (h)). The results
are similar in all Models A–C*.
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could occur without FGF2 dimerization. We will examine
binding pathways leading to both a 2:1:2 and 1:1:2 pro-
liferative signaling complex in future work.
CONCLUSION
Using available rate constants from literature, this model
suggests that the piecewise assemblage of a 2:2:2 FGF2:
HSPG:FGFR proliferative complex can occur in multiple
ways, and thus may be dependent upon the local environ-
ment surrounding FGF2 binding. This environment is charac-
terized by cell type, density, maturation, and the type and
expression of FGFRs and HSPGs on a given cell surface. It
also suggests that at relatively high concentrations of exo-
genous FGF2 (0.28 nM), there may be multistep processes
involved in the medium release, internalization, and LMW
fragment formation of HSPGs and FGF2-bound HSPGs.
This model also supports the notion of HSPG involvement in
the bioavailability of FGF2 through their metabolic process-
ing, which likely also accounts for the long half-life observed
with internalized FGF2. Experimental measurements of the
model estimated rate constants will have to be made to deter-
mine the relevance of these predictions.
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